GTHX - G1 Therapeutics Inc Stock Price, Fair Value and News

3.72USD-0.27 (-6.77%)Market Closed

Market Summary

USD3.72-0.27

Market Closed

-6.77%

GTHX Stock Price

View Fullscreen

GTHX RSI Chart

GTHX Valuation

Market Cap

194.2M

Price/Earnings (Trailing)

-4.05

Price/Sales (Trailing)

2.35

EV/EBITDA

-4.56

Price/Free Cashflow

-5.07

GTHX Price/Sales (Trailing)

GTHX Profitability

EBT Margin

-54.36%

Return on Equity

-135.55%

Return on Assets

-39.47%

Free Cashflow Yield

-19.74%

GTHX Fundamentals

GTHX Revenue

Revenue (TTM)

82.5M

Rev. Growth (Yr)

45.1%

Rev. Growth (Qtr)

20.92%

GTHX Earnings

Earnings (TTM)

-48.0M

Earnings Growth (Yr)

67.67%

Earnings Growth (Qtr)

40.24%

Breaking Down GTHX Revenue

Last 7 days

-9.3%

Last 30 days

-13.9%

Last 90 days

-1.8%

Trailing 12 Months

29.6%

How does GTHX drawdown profile look like?

GTHX Financial Health

Current Ratio

3.87

GTHX Investor Care

Shares Dilution (1Y)

1.05%

Diluted EPS (TTM)

-0.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	57.3M	89.2M	77.9M	82.5M
2022	24.2M	28.1M	46.8M	51.3M
2021	59.5M	64.0M	42.2M	31.5M
2020	0	15.4M	30.4M	45.3M
2015	0	0	0	522.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of G1 Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 20, 2024	thomas monica r.	acquired	-	-	37,500	general counsel
Mar 20, 2024	avagliano mark	acquired	-	-	100,000	chief business officer
Mar 20, 2024	umstead john w. v	acquired	-	-	37,500	chief financial officer
Mar 18, 2024	umstead john w. v	sold	-19,751	3.0169	-6,547	chief financial officer
Feb 12, 2024	malik rajesh	acquired	8,580	0.3	28,600	chief medical officer
Feb 12, 2024	malik rajesh	sold	-132,143	4.6204	-28,600	chief medical officer
Jan 04, 2024	malik rajesh	sold	-2,121	2.9423	-721	chief medical officer
Jan 04, 2024	avagliano mark	sold	-2,121	2.9423	-721	chief business officer
Jan 04, 2024	murdock terry l	sold	-2,121	2.9423	-721	chief operating officer
Jan 04, 2024	umstead john w. v	sold	-326	2.9423	-111	chief financial officer

Which funds bought or sold GTHX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Allworth Financial LP	unchanged	-	952	3,240	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-712,000	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-53,701	-	-%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	added	42.33	37,000	73,000	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	41.96	1,743,300	3,468,250	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	reduced	-6.84	32,853	135,696	-%
Apr 19, 2024	DENALI ADVISORS LLC	reduced	-29.31	462	371,952	0.11%
Apr 15, 2024	FRANKLIN STREET ADVISORS INC /NC	unchanged	-	106,000	360,000	0.03%
Apr 05, 2024	CWM, LLC	unchanged	-	1,000	6,000	-%
Mar 14, 2024	ABLES, IANNONE, MOORE & ASSOCIATES, INC.	new	-	14,433	14,433	0.01%

Are Funds Buying or Selling GTHX?

Are funds buying GTHX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GTHX

No. of Funds

Unveiling G1 Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 21, 2024	eshelman fredric n	8.13%	4,216,074	SC 13D/A
Feb 09, 2023	vanguard group inc	3.81%	1,925,845	SC 13G/A
Feb 03, 2023	state street corp	0.36%	179,736	SC 13G/A
Dec 06, 2022	jpmorgan chase & co	4.0%	2,045,814	SC 13G/A
Jul 11, 2022	state street corp	0.33%	142,206	SC 13G/A
Jul 08, 2022	blackrock inc.	3.2%	1,369,281	SC 13G
Feb 11, 2022	state street corp	10.12%	4,301,613	SC 13G/A
Feb 03, 2022	blackrock inc.	7.8%	3,310,212	SC 13G/A
Jan 21, 2022	jpmorgan chase & co	5.0%	2,139,848	SC 13G
Oct 12, 2021	state street corp	10.35%	4,383,612	SC 13G/A

Recent SEC filings of G1 Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 12, 2024	PRE 14A	PRE 14A
Apr 09, 2024	144	Notice of Insider Sale Intent
Mar 22, 2024	8-K	Current Report
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading

Peers (Alternatives to G1 Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

G1 Therapeutics Inc News

Latest updates

G1 Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2015Q4
Revenue	20.9%	14,873,000	12,300,000	42,392,000	12,946,000	10,250,000	23,576,000	10,573,000	6,902,000	5,796,000	4,858,000	6,604,000	14,218,000	16,546,000	26,599,000	2,140,000	-
Operating Expenses	-17.0%	23,802,000	28,668,000	30,876,000	38,692,000	41,137,000	45,124,000	47,535,000	53,683,000	43,382,000	46,002,000	44,796,000	39,753,000	40,634,000	36,344,000	32,962,000	-
S&GA Expenses	-9.6%	15,166,000	16,781,000	17,432,000	21,753,000	23,558,000	24,432,000	25,716,000	26,709,000	23,218,000	24,268,000	25,236,000	22,970,000	24,260,000	18,412,000	14,431,000	-
R&D Expenses	-16.2%	7,380,000	8,811,000	12,040,000	15,480,000	16,587,000	19,581,000	20,843,000	26,305,000	19,790,000	21,143,000	18,752,000	16,540,000	16,374,000	17,932,000	18,531,000	-
EBITDA Margin	42.4%	-0.43	-0.75	-0.73	-2.01	-2.68	-3.10	-5.86	-6.86	-4.58	-3.10	-1.56	-1.54	-	-	-	-
Interest Expenses	-2.8%	1,788,000	1,840,000	2,667,000	2,512,000	2,314,000	2,073,000	1,821,000	1,716,000	1,052,000	724,000	649,000	483,000	-	-	-	-
Income Taxes	-0.3%	902,000	905,000	1,308,000	-	481,000	1,219,000	-	-	246,000	321,000	220,000	138,000	479,000	931,000	-	-
Earnings Before Taxes	42.3%	-9,976,000	-17,299,000	10,018,000	-27,595,000	-33,168,000	-24,053,000	-39,446,000	-49,192,000	-39,774,000	-42,147,000	-39,202,000	-26,304,000	-24,868,000	-10,743,000	-31,210,000	-
EBT Margin	37.8%	-0.54	-0.87	-0.84	-2.17	-2.84	-3.25	-6.06	-7.05	-4.68	-3.14	-1.58	-1.57	-	-	-	-
Net Income	40.2%	-10,878,000	-18,204,000	8,710,000	-27,595,000	-33,649,000	-25,272,000	-39,446,000	-49,192,000	-40,020,000	-42,468,000	-39,422,000	-26,442,000	-25,347,000	-11,674,000	-31,210,000	-
Net Income Margin	36.0%	-0.58	-0.91	-0.87	-2.20	-2.88	-3.29	-6.08	-7.08	-4.71	-3.17	-1.61	-1.59	-	-	-	-
Free Cashflow	-20.9%	-12,792,000	-10,577,000	14,085,000	-29,053,000	-30,632,000	-21,247,000	-38,557,000	-38,184,000	-34,660,000	-34,080,000	-37,588,000	-27,980,000	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-8.7%	122	133	148	162	188	167	187	218	254	243	277	309	229	258	254	257	285	317	332	352	371
Current Assets	-8.8%	115	126	140	154	180	157	177	208	244	233	266	297	216	246	240	244	271	303	328	349	370
Cash Equivalents	-38.8%	32.00	53.00	56.00	68.00	95.00	93.00	144	183	221	212	244	279	207	238	234	242	269	300	325	348	369
Inventory	-7.8%	12.00	13.00	16.00	16.00	16.00	14.00	14.00	8.00	3.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-
Net PPE	-7.7%	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	4.00	4.00	2.00	1.00	1.00
Liabilities	-4.4%	86.00	90.00	90.00	117	119	121	121	118	111	65.00	64.00	63.00	51.00	61.00	50.00	27.00	29.00	31.00	19.00	13.00	12.00
Current Liabilities	-11.7%	30.00	34.00	34.00	34.00	36.00	37.00	37.00	35.00	28.00	27.00	26.00	26.00	23.00	33.00	22.00	18.00	20.00	21.00	18.00	12.00	12.00
Shareholder's Equity	-17.7%	35.00	43.00	58.00	45.00	69.00	46.00	66.00	100	144	178	213	245	177	197	204	229	256	286	313	339	359
Retained Earnings	-1.4%	-780	-769	-750	-759	-732	-698	-673	-633	-584	-544	-501	-462	-436	-410	-399	-367	-336	-301	-269	-238	-214
Additional Paid-In Capital	0.4%	815	812	808	805	801	744	739	734	728	723	715	708	613	608	603	597	592	588	582	577	573
Shares Outstanding	0.2%	52.00	52.00	52.00	52.00	51.00	43.00	43.00	43.00	42.00	42.00	42.00	41.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	128	-	-	-	209	-	-	-	845	-	-	-	821	-	-	-	853	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-20.9%	-12,792	-10,577	14,085	-29,053	-30,632	-21,247	-38,557	-38,184	-34,660	-34,080	-36,488	-26,880	-31,508	3,639	-28,848	-27,025	-30,011	-25,126	-22,888	-21,546	-21,228
Share Based Compensation	-12.2%	3,209	3,655	3,810	3,836	4,400	4,785	5,639	5,765	5,205	5,528	5,694	5,892	4,754	4,922	4,367	4,727	4,463	4,441	3,741	3,804	5,343
Cashflow From Investing	-206.2%	-7,647	7,201	346	2,910	-20,362	-29,661	-506	-	-	-	-	-	-	-	-	-	-1,100	-1,224	-176	-216	-111
Cashflow From Financing	54.5%	34.00	22.00	-26,754	-214	52,350	127	-	18.00	43,757	2,083	1,481	98,542	472	284	20,713	219	386	1,372	678	269	105

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GTHX Income Statement

2023-12-31

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues [Abstract]
Total revenues	$ 82,511	$ 51,301	$ 31,476
Operating Expenses [Abstract]
Cost of goods sold	7,195	3,748	2,016
Research and development	43,711	83,316	76,225
Selling, general and administrative	71,132	100,415	95,692
Total operating expenses	122,038	187,479	173,933
Loss from operations	(39,527)	(136,178)	(142,457)
Other income (expense)
Interest income	2,473	748	43
Interest expense	(10,038)	(10,432)	(4,667)
Other income (expense)	2,240	3	(346)
Total other income (expense), net	(5,325)	(9,681)	(4,970)
Loss before income taxes	(44,852)	(145,859)	(147,427)
Income tax expense	3,115	1,700	925
Net loss	$ (47,967)	$ (147,559)	$ (148,352)
Earnings Per Share [Abstract]
Basic (in usd per share)	$ (0.93)	$ (3.38)	$ (3.54)
Diluted (in usd per share)	$ (0.93)	$ (3.38)	$ (3.54)
Weighted Average Common Shares Outstanding [Abstract]
Basic (in shares)	51,733,487	43,626,113	41,943,417
Diluted (in shares)	51,733,487	43,626,113	41,943,417
Product sales, net
Revenues [Abstract]
Total revenues	$ 46,344	$ 31,337	$ 11,120
License revenue
Revenues [Abstract]
Total revenues	$ 36,167	$ 19,964	$ 20,356

GTHX Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 32,218,000	$ 94,594,000
Restricted cash	63,000	63,000
Marketable securities	49,938,000	50,476,000
Accounts receivable and unbilled receivables, net	12,687,000	11,094,000
Inventories, net	12,442,000	16,179,000
Prepaid expenses and other current assets	7,600,000	7,094,000
Total current assets	114,948,000	179,500,000
Property and equipment, net	1,476,000	1,989,000
Restricted cash	187,000	250,000
Operating lease assets	4,908,000	5,962,000
Other assets	21,000	264,000
Total assets	121,540,000	187,965,000
Current liabilities
Accounts payable	3,992,000	7,431,000
Accrued expenses	21,893,000	25,557,000
Deferred revenue	620,000	7,000
Other current liabilities	3,211,000	2,593,000
Total current liabilities	29,716,000	35,588,000
Loan payable	51,557,000	77,015,000
Deferred revenue	500,000	1,000,000
Operating lease liabilities	4,340,000	5,615,000
Other liabilities	41,000	0
Total liabilities	86,154,000	119,218,000
Stockholders’ equity
Common stock, $0.0001 par value, 120,000,000 shares authorized as of December 31, 2023, and December 31, 2022; 51,952,741 and 51,526,100 shares issued as of December 31, 2023, and December 31, 2022, respectively; 51,926,075 and 51,499,434 shares outstanding as of December 31, 2023, and December 31, 2022, respectively	5,000	5,000
Treasury stock, 26,666 shares as of December 31, 2023, and December 31, 2022	(8,000)	(8,000)
Additional paid-in capital	815,374,000	800,768,000
Accumulated deficit	(779,985,000)	(732,018,000)
Total stockholders’ equity	35,386,000	68,747,000
Total liabilities and stockholders' equity	$ 121,540,000	$ 187,965,000

About G1 Therapeutics Inc

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

CEO	Mr. John E. Bailey Jr.
WEBSITE	g1therapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	170

G1 Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for G1 Therapeutics Inc? What does GTHX stand for in stocks?

GTHX is the stock ticker symbol of G1 Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of G1 Therapeutics Inc (GTHX)?

As of Mon Apr 29 2024, market cap of G1 Therapeutics Inc is 194.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GTHX stock?

You can check GTHX's fair value in chart for subscribers.

What is the fair value of GTHX stock?

You can check GTHX's fair value in chart for subscribers. The fair value of G1 Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of G1 Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GTHX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is G1 Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether GTHX is over valued or under valued. Whether G1 Therapeutics Inc is cheap or expensive depends on the assumptions which impact G1 Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GTHX.

What is G1 Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, GTHX's PE ratio (Price to Earnings) is -4.05 and Price to Sales (PS) ratio is 2.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GTHX PE ratio will change depending on the future growth rate expectations of investors.